medicare coverage of glp-1 drugs Bridge Program Explained: Medications for Weight Loss GLP-1s and The Payer Predicament

By 2024, Ozempic had surpassed Trulicity, also approved for type 2 diabetes (not obesity) to make up the largest share of GLP-1 prescriptions and spending (39% in 2024)

Semaglutide and other GLP-1 drugs can cause side effects like nausea, diarrhoea, dizziness, stomach pain, and constipation

If aspiration is suspected, clinical assessment should focus on cough, hypoxemia, fever, tachypnea, wheezing, new infiltrates, or respiratory distress

Stay active regular walking improves insulin response

As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)

Length of treatment and patient adherence to taking medication are also important